Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Stock Has Average Price Target of $16.00 According to Analysts

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) has been given an average rating of “Buy” by the five research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $16.00.

LMRI has been the subject of several recent research reports. Wall Street Zen downgraded Lumexa Imaging from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. KeyCorp assumed coverage on Lumexa Imaging in a report on Thursday, September 24th. They issued an “overweight” rating and a $18.00 target price on the stock. UBS Group restated a “strong-buy” rating on shares of Lumexa Imaging in a research note on Monday. Weiss Ratings restated a “sell (d)” rating on shares of Lumexa Imaging in a report on Tuesday, September 22nd. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price objective on shares of Lumexa Imaging in a research note on Thursday, August 13th.

Lumexa Imaging Price Performance

LMRI stock opened at $10.30 on Monday. The stock has a market capitalization of $989.91 million and a PE ratio of -21.03. The company’s 50-day moving average is $11.32 and its 200-day moving average is $10.32. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45.

Lumexa Imaging (NASDAQ:LMRI) last issued its earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The firm had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities research analysts expect that Lumexa Imaging will post 0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Lumexa Imaging

Hedge funds have recently added to or reduced their stakes in the stock. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Lumexa Imaging during the 4th quarter worth approximately $27,750,000. Jupiter Topco LLC bought a new position in shares of Lumexa Imaging in the second quarter valued at approximately $24,269,000. Janus Henderson Group PLC boosted its position in shares of Lumexa Imaging by 5.4% during the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company’s stock valued at $18,063,000 after buying an additional 107,903 shares during the last quarter. BlackRock Inc. bought a new stake in Lumexa Imaging during the second quarter worth $15,771,000. Finally, Brigade Capital Management LP purchased a new stake in Lumexa Imaging in the 2nd quarter valued at $7,511,000.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is an outpatient diagnostic imaging company that provides medical imaging services to patients and referring healthcare providers in the United States. Its services are designed to support the diagnosis, monitoring and management of a wide range of medical conditions.

The company’s imaging capabilities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), ultrasound, mammography and X-ray services. Lumexa also provides related radiology and imaging-support services through its outpatient centers and other care-delivery arrangements.

Lumexa Imaging was formerly known as Akumin Inc and adopted the Lumexa Imaging name as part of its corporate rebranding.